Last reviewed 2026-06-01 · How we verify

laparoscopical l cuff closure

El-Galaa Military Medical Complex · Phase 1 active Biologic ✓ Verified Jun 2026

laparoscopical l cuff closure is a Biologic drug developed by El-Galaa Military Medical Complex. It is currently in Phase 1 development. Also known as: transvaginal cuff closure.

Laparoscopical l cuff closure is a treatment method used to address conditions such as vaginal cuff dehiscence, vaginal hematoma, and vaginal infection. This method involves the use of a small molecule intervention, specifically L-asparagine, which is administered laparoscopically to achieve closure.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	laparoscopical l cuff closure
Also known as	transvaginal cuff closure
Sponsor	El-Galaa Military Medical Complex
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Laparoscopic Versus Transvaginal Cuff Closure (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

laparoscopical l cuff closure CI brief — competitive landscape report
laparoscopical l cuff closure updates RSS · CI watch RSS
El-Galaa Military Medical Complex portfolio CI

Frequently asked questions about laparoscopical l cuff closure

What is laparoscopical l cuff closure?

laparoscopical l cuff closure is a Biologic drug developed by El-Galaa Military Medical Complex.

Who makes laparoscopical l cuff closure?

laparoscopical l cuff closure is developed by El-Galaa Military Medical Complex (see full El-Galaa Military Medical Complex pipeline at /company/el-galaa-military-medical-complex).

Is laparoscopical l cuff closure also known as anything else?

laparoscopical l cuff closure is also known as transvaginal cuff closure.

What development phase is laparoscopical l cuff closure in?

laparoscopical l cuff closure is in Phase 1.

Manufacturer: El-Galaa Military Medical Complex — full pipeline
Also known as: transvaginal cuff closure

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing